ArticleBrain & spine2026
Not all enhancing lesions are tumor recurrence: Foreign body granulomas after glioma resection.
Article in Brain & spine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Postoperative imaging surveillance is essential in the management of glioma patients. However, new or progressive contrast-enhancing lesions do not always indicate true tumor recurrence. Foreign body granulomas (FBG), also known as textilomas, may arise as inflammatory reactions to hemostatic or sealing materials used during surgery and can closely mimic tumor progression on MRI. Distinguishing between these entities remains a major diagnostic challenge with important therapeutic implications. Methods: We retrospectively analyzed glioma re-operations performed for suspected recurrence at a tertiary neurosurgical center between 2016 and 2020. Demographic data, tumor histology, intraoperative foreign material, adjuvant therapy, and time to re-operation were assessed. Histological findings were classified as recurrence or no tumor. Preoperative MRI was reviewed according to RANO criteria, with emphasis on diffusion-weighted imaging and apparent diffusion coefficient (ADC) values. Univariate analyses were conducted. Results: Of 211 glioma patients, 38 (18 %) underwent re-operation for suspected recurrence. Histological recurrence was confirmed in 27 cases (71.1 %), while 11 (28.9 %) showed no tumor. Foreign material was identified in three non-tumor cases; the remaining showed post-inflammatory or unclear changes. All non-tumor cases had been radiologically classified as progressive disease. ADC values tended to be lower in the non-tumor group, suggesting diffusion restriction, but without statistical significance. Oxidized cellulose was frequently used in both groups Conclusion: FBG are a relevant and likely underrecognized differential diagnosis in suspected glioma recurrence. Conventional MRI and RANO criteria alone may be insufficient. Diffusion-weighted imaging may provide additional clues but is not definitive. Increased awareness and multidisciplinary evaluation are essential to avoid unnecessary interventions and overtreatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.